STDs

Becton Dickinson and Euroclone aim to develop and commercialize the molecular assays for launch outside the US in 2018, and in the US at a later date.

The funding will be used to pay for clinical trials in the US that will be used as underlying evidence for FDA clearance of the test, the company said.

For the three months ended June 30, the point-of-care infectious disease diagnostics firm posted $4.1 million in total revenues, up from $3.3 million in Q2 2016.

The foundation will provide funding of no more than $20 million over the four-year term of the deal, and no more than $6 million each year. 

The agency cleared a handful of assays last month for the detection and diagnoses of toxoplasmosis, syphilis, sepsis, thyroid conditions, and other ailments. 

A total of 66 projects were awarded the funding as part of the Biomedical Catalyst 2016 funding. 

As SpeeDx preps for the European launch of its STI tests, it will incorporate UgenTec's automated data analysis tool for PCR applications.

The firm is launching the test for bacterial vaginosis in Europe, the Middle East, and North Africa.